Skip to content

Cost effectiveness of a collaborative stepped care intervention for anxiety disorders in the primary care setting.

Cost effectiveness of a collaborative stepped care intervention for anxiety disorders in the primary care setting. - CC:PAD

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON31723
Enrollment
174
Registered
2008-04-29
Start date
2008-05-01
Completion date
Unknown
Last updated
2024-05-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Generalised anxiety disorder panic disorder

Interventions

*Intervention(s): Evidence exists for effectiveness of stepped care in PD and GAD,(68) more specific for two of the three proposed steps. The effect size of the combined step 2 and three ranged betw

Sponsors

Zorgonderzoek Nederland (ZON)
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Patients who visit the GP practice and meet the DSM-IV diagnosis for GAD or PD are included in the study.

Exclusion criteria

Exclusion criteria: Suicidal, psychotic, cognitive deterioration.

Design outcomes

Primary

MeasureTime frame
*outcome parameters: Baseline measurememts: The mini-International Neuropsychiatric Interview (MINI 28;29) is administered for the classification of symptoms and the BAI for measurement of severity. Primary outcome measure is reduction of GAD or PD symptoms as measured by the BAI. Secondary outcome measures are remittance of GAD or PD as measured with MINI and the BAI (score below 10; range 0-61), adherence and compliance, and the Patient-Doctor Relationship Questionnaire (PDRQ-9). The number and intensity of functional somatic complaints a patient is experiencing is assessed with the LKV (Lichamelijke Klachten Vragenlijst),(33) the Somatosensory amplification Scale(34) and the Whitely Index.(35) Health care use is assessed by the Scale for Medical Utilisation of Health Services.

Secondary

MeasureTime frame
*Economic evaluation: The aim of this economic evaluation is to assess the cost effectiveness of collaborative stepped care in primary care of the treatment of GAD/PD. The results will be expressed as cost per unit of the BAI and as cost per Quality Adjusted Life Year (QALY). The economic evaluation will be undertaken from a societal perspective. Hence, all relevant effects and costs due to resource utilisation within the healthcare (direct medical costs) and costs due to production losses (productivity costs) will be included. The costs will be estimated in line with the Dutch guidelines for cost calculations in health care.(38)The TiC-P will be used for collecting data on health care utilisation as well as production losses.(36,37). The TiC-P is commonly applied in economic evaluations of treatments in mental health care. For instance, the TiC-P was recently used in a large naturalistic trial on the cost-utility of brief psychological treatment for depression and anxiety.(69) Furthermore, we will add a module of the Prodisq, a questionnaire for collecting data on production losses of paid work. Calculating the total direct medical costs, the total number of medical contacts (GP visits, outpatient visits, use of medication, etc.) will be multiplied by unit costs of the corresponding health care services. Reference unit prices of the corresponding health care services will be applied, and adjusted to the year of the study according to the consumer price index.(38) Since the collaborative stepped care model is new kind of intervention, a unit price per session is currently not available. To determine a reference price for this intervention, a micro-costing study will be performed. Therefore, we will perform measurements of time for face-to-face contacts with the patient as well as indirect time per contact. Indirect time per contact may consist of e.g. mutual consultations contacts between GP, casemanager and/or psychiatrist. Fur

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)